• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Sep. 12, 2013

View Archived Issues

Dopamine Road: Civitas’ $38M to Fill in Parkinson’s ‘Potholes’

With $38 million in Series B money, Civitas Therapeutics Inc.’s can finish its ongoing, 80-patient Phase IIb trial testing inhaled levodopa (L-dopa) in Parkinson’s disease patients, and get ready for a Phase III trial that would begin in the second half of next year. Read More

TCM Compound for IBS, Crohn’s Enters Phase III

SHANGHAI – A joint venture between a Chinese and a Swiss company has launched Phase III trials for a botanical drug to treat inflammatory bowel disease. Read More

Prometic Secures $10M for GMP Facility

Prometic Life Sciences Inc., of Laval, Quebec, will earmark a portion of the proceeds from a $10 million financing from Thomvest Seed Capital Inc. to commission its GMP facility for manufacture of plasma-derived orphan drugs. Read More

To the ‘Imaxio’: Vaccine Technology Seeks Immune Boost

After a decade of work, French vaccine developer Imaxio SA achieved a significant milestone when IMX313, its pro-immunogenic technology, was administered for the first time in humans in a Phase I tuberculosis (TB) vaccine trial. Read More

Induced Stem Cells Made Directly in Mice

Since their initial description in 2007, induced pluripotent stem (iPS) cells have been investigated as a possible alternative to embryonic stem cells. By adding a cocktail of so-called reprogramming factors, scientists can turn mature cells – most often skin cells – into pluripotent cells that can turn into many different cell types. Read More

Other News To Note

• Hedgepath Pharmaceuticals Inc., (HPPI) of Tampa, Fla., said it signed an exclusive supply and license deal with Mayne Pharma International Pty. Ltd., a subsidiary of Melbourne, Australia-based Mayne Pharma Group Ltd., whereby HPPI will pursue clinical development of Mayne’s formulation of itraconazole, known as Suba-Itraconazole, for the treatment of a variety of cancers, with a focus on seeking regulatory approvals and marketing in the U.S. Read More

Stock Movers

Read More

Clinic Roundup

• Ovascience Inc., of Cambridge, Mass., suspended enrollment of a trial with Augment, its candidate designed to improve egg quality and increase the success of in vitro fertilization, because the FDA questioned the status of the product as a human cellular tissue-based product and wants the firm to file an investigational new drug application. Read More

Washington Roundup

• A new analysis from the Tufts Center for the Study of Drug Development (CSDD) showed that while lack of commercial viability is the leading cause of Phase I failures for new drug candidates, efficacy issues lead as the reason behind Phase II failures. Read More

ICAAC Roundup

• Chimerix Inc., of Durham, N.C., disclosed results from its exploratory Phase II Study 202 evaluating brincidofovir (CMX001) in hematopoietic cell transplant (HCT) recipients with early adenovirus (AdV) infection. Read More

Pharma: Other News To Note

• Merck and Co. Inc., of Whitehouse Station, N.J., licensed its oral small-molecule inhibitor of WEE1 kinase (MK-1775) to Astrazeneca plc, of London. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 20, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 18, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 17, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Enflonsia

    Merck wins FDA approval in pediatric RSV and steps into CDC uncertainty

    BioWorld
    With the U.S. FDA’s approval of Enflonsia (clesrovimab) to prevent respiratory syncytial virus (RSV) infection lower respiratory tract disease in newborns and...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe